Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism

Karine Aouchiche (1) , Rachel Reynaud (2, 3, 4) , Vincent Amodru (2, 3, 5) , Thierry Brue (2, 5, 3) , Thomas Cuny (2, 3, 5)

1 AMU SMPM MED - Aix-Marseille Université - École de médecine
2 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
3 MarMaRa - Institut Marseille Maladies Rares
4 Service de pédiatrie multidisciplinaire [Hôpital de la Timone Enfants - APHM]
5 Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]

Context Hypoparathyroidism (hypoPTH) in adults is mainly due to total thyroidectomy. Conventional therapies (calcium, active vitamin D) can fail to normalize calcemia, expose the patient to hypercalciuria and impact quality-of-life. Human parathormone (PTH) replacement therapy is a suitable option in these cases, although few clinical reports have been published so far. Methods We describe two cases of patients with refractory postsurgical hypoPTH, in whom subcutaneous infusion of recombinant PTH (teriparatide) through the Omnipod® pump was initiated after failure of all other therapeutic options. Besides, we performed a review of literature of hypoPTH cases treated by continuous infusion of teriparatide. Results Two women aged 46 and 61 years old failed to normalize calcemia either with conventional treatments (calcium 8 g/day + calcitriol 9 mcg/day and calcium 5 g/day + calcitriol 12 mcg/day) or with thrice daily subcutaneous injections of teriparatide. As a last resort, teriparatide infusion via Omnipod® device normalized their calcemia and allowed calcium/vitamin D withdrawal, with average teriparatide dose of 23 and 32 mcg/day, respectively. The flow of teriparatide was adapted according to a protocol based on measured calcemia, under medical supervision. In the literature, 15 adult cases (13 women, mean age 44.5 ± 5.2 years old) are reported. HypoPTH was consecutive to surgery in all of them. Mean dose of teriparatide administered was 25 ± 6 mcg/day with improvement of calcemia level and quality-of-life in all patients. Conclusions Continuous administration of teriparatide through Omnipod® appears as an efficient therapeutic option in refractory hypoPTH, whose administration to the patient can be assisted by medically-supervised protocol.

Domaines: Génétique

Karine Aouchiche, Rachel Reynaud, Vincent Amodru, Thierry Brue, Thomas Cuny. Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism. Endocrine, 2022, 76 (1), pp.179-188. ⟨10.1007/s12020-021-02978-6⟩. ⟨hal-03780218⟩